Viking Therapeutics, Inc. (VKTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Company Overview - Viking Therapeutics is actively engaged in the biotechnology sector, focusing on obesity treatment through ongoing clinical trials [3]. Clinical Trials - The company has two Phase III trials currently underway for obesity, which were initiated in the second quarter and are reportedly enrolling well [3]. - A recent Phase IIa trial demonstrated promising results, showing up to 12% weight loss over a 13-week period with good tolerability for the oral formulation of the compound being tested in Phase III [4]. Future Plans - The next steps for the oral program include scheduling an end-of-Phase II meeting with regulatory authorities to discuss the path forward [4].